Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Head of Research | February 13, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-02-13 | Direct | 8,450 |
Reported balance
After 2026-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 8,450 · Balance 8,450 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2026 Filed Feb 18, 2026 01:10 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 8,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000029 · form4.xml · derivative · entry 1 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,450 Underlying: Common Stock · 8,450 shares Expires 2029-02-13 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:59 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,873 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000018 · form4.xml · derivative · entry 6 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,747 Underlying: Common Stock · 1,873 shares Expires 2028-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:59 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,385 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000018 · form4.xml · derivative · entry 5 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,385 Underlying: Common Stock · 1,385 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:59 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 584 | $201.18 | $117,489.12 |
DisclosureSEC source: 0000875045-26-000018 · form4.xml · nonDerivative · entry 4 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,058 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:59 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,873 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000018 · form4.xml · nonDerivative · entry 3 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:59 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 407 | $201.18 | $81,880.26 |
DisclosureSEC source: 0000875045-26-000018 · form4.xml · nonDerivative · entry 2 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,769 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:59 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,385 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000018 · form4.xml · nonDerivative · entry 1 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 21:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 695 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-25-000051 · form4.xml · derivative · entry 3 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 695 Underlying: Common Stock · 695 shares Expires 2026-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of November 1, 2023. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 21:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 337 | $154.27 | $51,988.99 |
DisclosureSEC source: 0000875045-25-000051 · form4.xml · nonDerivative · entry 2 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,791 Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 21:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 695 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-25-000051 · form4.xml · nonDerivative · entry 1 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:52 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,385 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003961 · form4.xml · derivative · entry 4 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,770 Underlying: Common Stock · 1,385 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:52 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 443 | $141.35 | $62,618.05 |
DisclosureSEC source: 0001127602-25-003961 · form4.xml · nonDerivative · entry 2 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,433 Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:52 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,385 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003961 · form4.xml · nonDerivative · entry 1 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 23:52 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 5,620 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003961 · form4.xml · derivative · entry 3 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,620 Underlying: Common Stock · 5,620 shares Expires 2028-02-06 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:39 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 695 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-026385 · form4.xml · derivative · entry 3 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,390 Underlying: Common Stock · 695 shares Expires 2026-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of November 1, 2023. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:39 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 204 | $173.79 | $35,453.16 |
DisclosureSEC source: 0001127602-24-026385 · form4.xml · nonDerivative · entry 2 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 491 Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:39 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 695 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-026385 · form4.xml · nonDerivative · entry 1 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2024 Filed Feb 10, 2024 01:12 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 4,155 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004309 · form4.xml · derivative · entry 1 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,155 Underlying: Common Stock · 4,155 shares Expires 2027-02-07 F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 21:06 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 2,085 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-026781 · form4.xml · derivative · entry 2 Grogan Jane · CIK 0001995547 · Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,085 Underlying: Common Stock · 2,085 shares Expires 2026-11-01 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of November 1, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.